# Safety and Pharmacokinetic (PK) Study to Assess Bronchopulmonary Disposition of IV Eravacycline (TP-434) in Healthy Men and Women

> **NCT01989949** · PHASE1 · COMPLETED · sponsor: **Tetraphase Pharmaceuticals, Inc** · enrollment: 20 (actual)

## Conditions studied

- Normal Drug Tolerance

## Interventions

- **DRUG:** TP-434 (Eravacycline) reconstituted and administered via an IV infusion

## Key facts

- **NCT ID:** NCT01989949
- **Lead sponsor:** Tetraphase Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2013-01
- **Final completion:** 2013-04
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2021-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01989949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01989949, "Safety and Pharmacokinetic (PK) Study to Assess Bronchopulmonary Disposition of IV Eravacycline (TP-434) in Healthy Men and Women". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01989949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*